23andMe | Investor Presentation Deck | 57 slides · page 46 of 57
The slide outlines the mechanism of action, clinical rationale, and upcoming Phase 2a study design for the drug candidate.
Pitch deck · solution · present_solution · balanced density
Slide locked Sign in to view
Slide schematic 3/3
disclaimer 1/1 list 1/1 title 1/1
Components 3
disclaimer bullet headline
Tools 1
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.